Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358669 | 1.00 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL29133372 | 1.00 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL30358680 | 1.00 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL29133404 | 1.00 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL24602613 | 0.88 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL31103493 | 0.88 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL17210329 | 0.88 | ESR2 (0.46) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL26914838 | 0.86 | ESR2 (0.45) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL29781230 | 0.83 | ESR2 (0.43) | ESR2NR1H2NAMPTABHD6MAPK1 | |
| SCHEMBL12540757 | 0.83 | ESR2 (0.43) | ESR2NR1H2NAMPTABHD6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4182032-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| CN-115835910-A | Hydrogenated isoquinoline or naphthyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20160368933-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9359355-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20140163052-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8623885-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163052-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NR1H2 2448/4885NAMPT 1826/4885 |
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, H1-3, HRH4 | ESR2 3549/4885NR1H2 1048/4885NAMPT 2175/4885 |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NR1H2 2448/4885NAMPT 1826/4885 |
| US-20160368933-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | ESR2 2184/4885NR1H2 2448/4885NAMPT 1826/4885 |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | ESR2 2061/4885NR1H2 3798/4885NAMPT 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.